论文部分内容阅读
目的观察放疗联合紫杉醇与卡铂同步化疗对中晚期宫颈癌的临床效果及安全性。方法选择2009年1月至2013年12月在湖南省肿瘤医院进行治疗的中晚期宫颈癌患者46例为观察组,患者均接受放疗联合紫杉醇、卡铂同步化疗。根据病例对照的原则,选择年龄、卡氏评分等与观察组资料均衡的、行单纯放疗的宫颈癌患者46例为对照组。对比两组的临床效果及安全性。结果观察组患者近期疗效显著优于对照组,差异有统计学意义(P<0.05);观察组发生骨髓抑制、胃肠道反应程度重于对照组(P均<0.05);两组放射性肠炎、膀胱炎发生率差异无统计学意义(P>0.05)。观察组患者5年生存率高于对照组(P<0.05),局部复发率和远处转移率低于对照组(P均<0.05)。结论放疗联合紫杉醇、卡铂同步化疗治疗中晚期宫颈癌效果显著,患者耐受性好,不良反应程度较轻。
Objective To observe the clinical efficacy and safety of concurrent radiotherapy combined with paclitaxel and carboplatin in the treatment of advanced cervical cancer. Methods 46 patients with advanced cervical cancer who were treated in Hunan Cancer Hospital from January 2009 to December 2013 were selected as the observation group. All patients underwent radiotherapy combined with paclitaxel and carboplatin simultaneously. According to the principle of case control, 46 patients with cervical cancer who underwent radiotherapy alone were selected as the control group according to the data of age, Karnofsky score and observation group. The clinical effects and safety of the two groups were compared. Results The efficacy of the observation group was significantly better than that of the control group (P <0.05). The bone marrow suppression and gastrointestinal reaction in the observation group were more severe than those in the control group (P <0.05) The incidence of cystitis was not statistically significant (P> 0.05). The 5-year survival rate in the observation group was higher than that in the control group (P <0.05), and the local recurrence rate and distant metastasis rate were lower than those in the control group (all P <0.05). Conclusions Radiotherapy combined with paclitaxel and carboplatin in the treatment of advanced cervical cancer is effective, and the patients are well tolerated with less adverse reactions.